Home > Professionals > Courses > Part II
Part II: Mastering the Protocols for Optimization of Hormone
Replacement Therapy - Advanced Protocols

March 24th – 26th, 2017 - Salt Lake City, Utah
September 22nd-24th, 2017 — Chicago, IL

For All Details, Fee's & Registration:http://worldlinkmedical.com/live-cme-courses/part-ii/

This course has been approved for:
21 AMA PRA Category 1 Credits,
21 Nursing Contact Hours (21 pharmacologic hours),
20 Hours Pharmacy Credit (knowledge based)

Part I - Part Two follows the Part One series with advanced concepts and up-to-date research.

This two and one-half day seminar will keep you current on the appropriate skills needed to manage everyday problems. Included in Part Two is an hour-long lecture that reviews the scientific literature giving credence for this type of practice. You will also find a new level of confidence as you move from the basics of Part I to the advanced protocols in Part II. The Part II course provides the experienced practitioner with training that is essential for mastering complex cases. The course will serve as a short refresher, but will highlight new important therapies, clinical pearls, tricks of the trade, controversies and everything that I could not cram into
Part I that you still need to know. The field of age management medicine continues to grow at a rapid rate, and we only seem to get busier, making it difficult to stay abreast of all the changes. This is why we’ve condensed an inordinate amount of material into 2 1⁄2 days—in fact, there are over 1,300 slides of information.

Course Objectives:

Objectives: Upon completion of this workshop, the health care professional will be able to:

1. Review new and additional studies not presented in Part I of advanced protocols for more complex cases beyond Part I.

2. Identify important issues in the relationship between hormones and cancer: cause or effect, provocation or protection? Safety and efficacy of estrogen in breast cancer survivors. What levels of progesterone are best for breast cancer protection? Which hormones protect against breast cancer?

3. Formulate recommendations for difficult cases presenting with multiple disease processes and the potential benefits of hormones in preventing and treating CAD, CVD, & DM.

4. Discuss literature citing new indications, risks, benefits and complications of estrogen, progesterone and testosterone therapy and how to avoid those minor side effects.

5. Compare and contrast different dosing strategies for estrogen and progesterone, including new and specific approaches to these therapies for both oral and transdermal and the pros and cons of each.

6. Describe important aspects of the WHI findings: Review comments from the experts that refute the results and extrapolation of this study to younger women, and other factors not included in the trials that would change the conclusions.

7. Review a literature update of hormones including new and different approaches to thyroid hormone replacement and disease prevention of CVD, hyperlipidemia, and osteoporosis.

8. Discuss over 40 articles that demonstrate thyroid replacement does not cause osteoporosis, even in TSH suppressive doses. Review the data demonstrating the importance of optimizing T3 levels for CVD protection, lowering cholesterol, increasing cardiac output, and decreasing SVR.

9. Identify various new therapies in the treatment for obesity, CFS, fibromyalgia.

10. Evaluate the epidemiology of cardiovascular disease and diabetes and the various treatment strategies as they pertain to medication, diet, exercise, lifestyle change, nutritional supplements, and non-drug therapies to stop the progression of disease.

11. Explore the role of omega 3 fatty acids, antioxidants, and glucose metabolism and how they influence insulin, inflammation, disease progression and atherosclerosis.

12. Describe the strategies for using the new cardiovascular risk markers, inflammation markers, new lipid parameters, NMR panel, and how to make sense of all the new lipid fractionation components.

13. Identify the roles of niacin and EFA in diabetes and atherosclerosis along with alternatives to statins.

14. Recognize the importance of various vitamins, supplements, and red yeast rice for CVD protection.

15. Determine current screening methods and management strategies of the most common premenopausal hormone disorder, Polycystic Ovary Syndrome (PCOS).

16. Implement various testing strategies for PCOS so that you never miss another case.

17. Review treatment regimens for hirsutism and hair loss in men and women.

18. Evaluate the literature that demonstrates successful treatment of osteoporosis using hormone replacement therapy, vitamin K, strontium, ipraflavone and not biphosphonates.

19. Review the positives and negatives of BHRT, why and how BHRT doesn’t work, and how to use EBM to make it work.

20. Identify current indications, risks and benefits of using cortisol for the treatment of chronic fatigue. Monitoring CFS and adrenal reserve via the ACTH stimulation test and saliva testing.

21. Determine rational approaches for the evaluation of fatigue with emphasis on cellular hypofunction (receptor site resistance) as it pertains to thyroid hormone and cortisol.

22. Describe, based on the literature, when to use oral vs. saliva testing to diagnose adrenal fatigue as well as treatment options for adrenal fatigue.

23. Describe, based on the literature, when not to use saliva testing to monitor hormone replacement therapy.

24. Utilize the knowledge gained to improve patient outcomes in BHRT followed by 100 questions and answers beyond Part I.

25. Review the lack of literature support for lowering estrogen in men and the harm of doing so. Optimal estrogen is just as important as optimal testosterone in both men and women.

26. Review the literature proving harm when progesterone is used to treat men in spite of other academies promoting its use.

27. Review the harm of using estriol over estradiol in spite of other academies promoting its use.

28. Realize that saliva levels correlate well for baseline testing of hormones whereas the literature shows no correlation with monitoring transdermal replacement of hormones.